2Anno
I can also name Novartis. With a forward PE of 12. However, EV/Ebitda is somewhat higher in comparison than at the companies you mentioned
••
2Anno
@Snostrich Novartis is at the top of my watch list. The share is really far too cheap, even from a historical perspective. I came to Bristol Myers with the same thought and it's doing great so far.
•
22
•